A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK

Two 'breakthrough' medicines have no worthwhile benefits, scientists say - so where do hopes really lie?